3 Bright Buys In This Brutal Bear Market: AstraZeneca plc, EMIS Group Plc And OptiBiotix Health PLC

Why canny investors should look to AstraZeneca plc (LON:AZN), EMIS Group Plc (LON:EMIS) and OptiBiotix Health PLC (LON:OPTI).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Some of the most experienced investors around (including renowned fund manager Neil Woodford) have long held the view that global economic growth will be sluggish as far ahead as the eye can see. That view appears to be on the mark with downgraded economic forecasts showing a humdrum outlook at best and a potential derailing of the post-financial-crisis recovery at worst.

In such an environment, companies in defensive sectors with relatively dependable earnings and dividends, can provide returns that are hard to come by in other areas of the market. Companies whose growth prospects will be largely determined by their own progress, rather than by the macroeconomic background, can also provide such returns.

Three companies that fit the bill, and which could be well worth buying today, are AstraZeneca (LSE: AZN), EMIS Group (LSE: EMIS) and OptiBiotix Health (LSE: OPTI).

AstraZeneca

Big pharma is a classic defensive sector, although a spate of patent expiries on a crop of the industry’s blockbuster drugs has rather masked the fundamental attractiveness of pharmaceutical giants and dampened their earnings and share-price performances in recent years.

AstraZeneca’s future is beginning to look brighter again as it deals with the loss of patent protection for star turns Nexium, Crestor and Seroquel. Earnings declines are bottoming out, and a promising pipeline of new products, and recent deals, including a majority stake in Acerta Pharma and the acquisition of ZS Pharma, are set to drive strong top-line and bottom-line growth from next year.

At a current share price of around 4,300p, Astra trades on 15 times forecast 2017 earnings and offers a healthy prospective dividend yield of 4.3%, which adds up to a good deal for investors, based on growth projections through to the next decade.

EMIS Group

EMIS is the UK leader in “connected healthcare software and services”, and is well-positioned for growth in a tough environment. Its technology enables clinicians to share vital information in healthcare settings from primary and community care, to high street pharmacies, secondary care and specialist services. The NHS’s perpetual battle to manage costs and improve efficiency provides a strong underpin for EMIS’s growth.

The company has been delivering regular annual top-line and bottom-line growth in double-digits, which is set to continue. However, the shares fell by as much as 16% early today following the release of the company’s year-end trading update. The annual consensus had been for 16% revenue growth for the year, but management said growth came in at 13%, having been held back by the timing of contracts within secondary care, and it also expects to report a partial (non-cash) impairment in goodwill for the division.

However, these negatives appear relatively minor. Overall trading was in line with management expectations, and the company has “maintained its customarily strong revenue visibility, order book and pipeline”. EMIS remains an attractive steady-growth story for all seasons. The shares have recovered somewhat from their early drop today, and the company appears a solid buy at 980p on 19.6 times forecast 2016 earnings with a prospective dividend yield of 2.4%.

OptiBiotix Health

OptiBiotix is very much one of those companies I referred to earlier, whose growth prospects will be largely determined by their own progress, rather than by the macroeconomic background.

This small-cap firm is valued at around £55m at a share price of 73p. It’s a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes. The company has no revenues as yet, but its portfolio of patents on compounds that change the way that microbes in the body work and interact is receiving considerable interest from some big players.

There’s an option agreement on OptiBiotix’s cholesterol-reducing product “with a multinational consumer goods company” (rumoured to be US giant Procter & Gamble). Meanwhile KSF Acquisition, with whom OptiBiotix announced a commercial agreement last week, may not be quite as familiar a name as P&G, but a note at the foot of the announcement reveals that KSF is “an investee of Kainos Capital, with a responsibility for the SlimFast brand in the UK, Ireland and Germany”.

OptiBiotix’s products appear to have considerable promise, and if deals with the likes of P&G and SlimFast progress, this small-cap company should grow rapidly whatever the macroeconomic background.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »